HYBIO: Signed a series of commercialization agreements with Sanofi, with the weight loss drug expected to reach a peak annual sales of 30 million units
On August 19th, HYBIO officially signed a series of commercialization documents including the "Contract Manufacturing and Supply Agreement for Semaglutide Injection" and the "Quality Agreement" with Zhejiang SanSheng ManDi Pharmaceutical Co., Ltd. in Beijing. According to the agreement, the supply price will be based on non-binding sales forecasts, with phased cost calculations and tiered pricing according to annual purchase volumes of ≤5 million, 5–10 million, and >10 million units, with an expected annual sales peak of 30 million units. The Semaglutide Injection for this cooperation will be filed as a Class 2 modified new drug and will be produced concurrently in China and the United States
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments